Zoetis Launches Portela for Feline Osteoarthritis in Canada and EU

Key Facts

In a move that strengthens its position in the global animal health sector, Zoetis has announced the commercial launch of Portela (relfovetmab) in Canada and European Union member states. This innovative medication targets osteoarthritis pain in cats, representing the first long-acting monoclonal antibody therapy in this field. According to reports, Portela provides sustained pain relief for up to three months with a single injection, significantly reducing the treatment burden for pet owners.

This expansion into Canadian and European markets follows nearly a decade of intensive research by the company into monoclonal antibody technologies. The launch aims to provide long-term therapeutic solutions in key markets, potentially driving revenue growth for the pharmaceutical giant. This step is part of Zoetis's strategy to enhance its portfolio of specialized pet treatments across major international markets.

Regarding market performance, ZTS stock stood at $75.35 at the close of July 21, 2026, with trading ranging between $74.56 and $76.46 during the session. Looking at economic catalysts in the launch regions, recent market data shows that the Bank of Canada (BoC) maintained interest rates at 2.25% during its July 15, 2026 meeting, which serves as a relevant factor in the company's operating environment within the Canadian market.